Related Experiment Video

Updated: Jun 1, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview

S Sartini1, B Dario, M Morelli

  • 1Dipartimento di Scienze Farmaceutiche, Università di Pisa, Via Bonanno 6, 56126, Pisa, Italy.

Current Medicinal Chemistry
|June 10, 2011
PubMed

Insights

Kit, a tyrosine kinase receptor, drives tumor growth through mutations. Inhibitors targeting Kit show promise, especially for gastrointestinal stromal tumors (GISTs), with this review detailing Kit

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The Kit receptor tyrosine kinase plays a crucial role in cell signaling and is implicated in various human cancers due to activating mutations.
  • Gain-of-function mutations in Kit are oncogenic drivers, making it a significant therapeutic target.
  • Gastrointestinal stromal tumors (GISTs) are a primary example where Kit mutations are pathognomonic.

Purpose of the Study:

  • To review the structural and signaling properties of wild-type and mutant Kit.
  • To elucidate the role of Kit in human cancer development, with a focus on GISTs.
  • To discuss the latest advancements in understanding GIST aetiopathogenesis and therapeutic strategies.

Main Methods:

  • Literature review of scientific publications on Kit signaling, mutations, and cancer.
  • Analysis of structural and functional data of Kit.
  • Synthesis of current research on GISTs, including molecular mechanisms and treatment outcomes.

Main Results:

  • Kit's aberrant activation through mutations drives tumorigenesis in various cancers.
  • Detailed understanding of Kit's structure and signaling pathways provides insights into its oncogenic potential.
  • Significant progress has been made in developing targeted therapies for Kit-driven tumors, particularly GISTs.

Conclusions:

  • Targeting Kit represents a validated and effective therapeutic strategy for specific cancers.
  • Continued research into Kit's biology and its role in GISTs is crucial for refining treatment approaches.
  • The development of Kit inhibitors has revolutionized the management of GISTs and holds promise for other Kit-dependent malignancies.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity: